Follistatin 344 (FS-344) is the longest form of follistatin, a natural protein that binds and neutralizes myostatin and activin. Myostatin is the body's brake on muscle growth, so blocking it is one of the most-studied ideas in muscle biology. Vials labeled "follistatin 344" are sold online as a shortcut to that effect.
It is a protein, not a peptide. Follistatin's precursor is 344 amino acids long and the circulating form is 315. FDA's definition in 21 CFR 600.3(h)(6) puts anything above 40 amino acids in the protein category, which means a biological product, not a compoundable peptide.
The dramatic results are from genetics, not injections. Myostatin-knockout mice carry muscles two to three times normal weight. Follistatin-transgenic mice, transgenic pigs and gene-therapy monkeys all grew muscle. In every case the follistatin was produced continuously by cells, not injected.
Human follistatin trials are gene therapy in disease, and they are small. Six people with Becker muscular dystrophy and six with sporadic inclusion body myositis received a one-time viral gene transfer into the thigh muscles. Walking distance improved in most, but not all, participants.
The one follistatin-based drug that reached randomized trials failed on function. ACE-083 reliably grew the injected muscle on imaging in facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease, then was discontinued because the functional endpoints were not met.
There is no published human study of injected follistatin 344 for muscle growth. The only human data on the injected product is harm: eleven bodybuilders developed a retinal condition after injecting it.
Status in 2026: no FDA-approved follistatin product of any kind, not on the HHS peptide compounding list, and prohibited in sport at all times under WADA category S4.3.
This PeptIQ.io guide was written on November 16, 2026 from PubMed, ClinicalTrials.gov, the Code of Federal Regulations, FDA enforcement records and the WADA Prohibited List. It contains no dosing information.
Talk to a licensed clinician before using anything sold as follistatin.
What Is Follistatin 344?
Follistatin was first purified in 1987 from ovarian fluid, where it suppressed follicle-stimulating hormone release. When researchers cloned it, they found the gene produces more than one version: a 344-amino-acid precursor and a shorter 317-amino-acid one, with a mature sequence of 315 amino acids. Those numbers are where the product names come from. FS-344 is the longer transcript; FST-315 is the main circulating form; FST-288 is a shorter variant that sticks to cell surfaces rather than travelling in the blood.
The isoforms are not interchangeable. In a 2006 Endocrinology study, all of them bound activin with comparable affinity, but their binding to cell surfaces differed sharply, and one isoform suppressed while another enhanced activin-driven cell growth. Myostatin competed for follistatin binding far more strongly than most bone morphogenetic proteins did.
PeptIQ.io / Follistatin 344 / 01
A brake, and the protein that blocks it.
Follistatin does not push muscle growth. It removes a signal that limits it. Every dramatic result in this field comes from cells that make follistatin continuously, not from a vial.
Step 01
Muscle makes myostatin
Myostatin (GDF-8) is produced almost only in skeletal muscle. Mice bred without it carry muscles two to three times normal weight.
Step 02
It binds activin type II receptors
That binding is the signal that holds muscle growth back. It is the brake, and it works the same way in every mammal studied.
Step 03
Follistatin sequesters it
Follistatin binds myostatin and activin before they reach the receptor. Animals engineered to make extra follistatin in muscle grow much larger muscles.
Which follistatin?
344 is the precursor. 315 circulates.
A third form, FST-288, binds cell surfaces instead. The isoforms behave differently, so the label on a vial does not settle what is in it.
Above 40 amino acids, FDA calls it a protein, not a peptide.
Evidence, not marketing.Nov 2026
Sources: McPherron, Lawler and Lee, Nature 1997 (PubMed 9139826); Lee and McPherron, PNAS 2001 (PubMed 11459935); Sidis et al., Endocrinology 2006 (PubMed 16627583). Simplified for education; not treatment advice.
So "follistatin" is not one molecule with one effect. It is a family of related proteins whose behavior depends on which form reaches which tissue, and gene-therapy researchers chose FS-344 on purpose: it yields a protein that is secreted into the circulation instead of binding cell surfaces, which was expected to avoid follistatin's unwanted effects on reproductive hormones.
Why Myostatin Is the Target
In 1997, a Johns Hopkins team described a new growth factor made almost only in skeletal muscle, GDF-8, now known as myostatin. Mice bred without it were visibly larger, with individual muscles weighing two to three times those of normal mice, from both bigger fibers and more of them.
Follistatin sits on the other side of that switch. A 2001 PNAS paper showed myostatin works by binding activin type II receptors, and that follistatin blocks that binding. Mice engineered to make extra follistatin in their muscles showed "dramatic increases in muscle mass comparable to those seen in myostatin knockout mice."
The effect is not limited to rodents. Duroc pigs engineered to make human follistatin-344 in muscle had significantly higher lean meat percentage than normal pigs (about 73% versus 69%), with larger fibers and no heart enlargement or reproductive problems reported.
Note what all of those experiments have in common: the follistatin is made by the animal's own cells, continuously, from birth or from a single gene transfer. None of them involved injecting follistatin protein from a vial.
What the Human Evidence Actually Shows
PeptIQ.io / Follistatin 344 / 02
The ladder breaks on the way to people.
Each rung down is a step closer to what is actually sold online, and a step away from evidence that it works.
Animals and genetics
Myostatin-knockout mice, follistatin-transgenic mice and transgenic pigs all grew substantially more muscle. The protein was made by their own cells.
Strong
Gene therapy in muscle disease
Six people with Becker muscular dystrophy and six with inclusion body myositis received a one-time gene transfer into the thigh. Most, not all, walked farther. Open-label, no placebo.
Early
Randomized trials of a follistatin-based drug
ACE-083 grew the injected muscle on imaging in two phase 2 trials, then was terminated: the functional endpoints were not met.
Failed on function
Injected follistatin 344 in healthy people
No published trial as of Nov 16, 2026. The only human data on the injected product is a case series of eye injury.
Untested
Evidence, not marketing.Nov 2026
Sources: Mendell et al., Mol Ther 2015 (PubMed 25322757) and 2017 (PubMed 28279643); Glasser et al., Muscle Nerve 2018 (PubMed 29486514); Statland et al., Muscle Nerve 2022 (PubMed 35428982); Thomas et al., Neurology 2022 (PubMed 35545446); ClinicalTrials.gov NCT02927080, NCT03124459 and NCT03943290 (terminated); PubMed and ClinicalTrials.gov searches, Nov 16, 2026.
Gene therapy in muscle disease (early-phase, small). Researchers at Nationwide Children's Hospital delivered the FS-344 gene into both thigh muscles using a viral vector.
In a phase 1/2a Becker muscular dystrophy trial published in Molecular Therapy in 2015, six patients were treated in two groups of three. Four improved on the six-minute walk test (by 58, 125, 108 and 29 meters); two showed no improvement. Muscle biopsies showed less fibrosis and more normal fiber size. No adverse effects were reported.
In a sporadic inclusion body myositis trial published in 2017, six treated patients gained a median of 56 meters per year on the same walk test, while eight untreated comparison patients lost about 26 meters per year. Two of the six treated patients barely changed. The authors noted that more advanced disease "poses challenges."
Both cohorts sit under ClinicalTrials.gov NCT01519349 (completed, 15 participants). A separate Duchenne trial, NCT02354781, treated three participants and is also complete.
These are real results, but they are open-label, tiny, and in people whose muscle is being destroyed by disease. They test a one-time gene transfer into a specific muscle, which is a different intervention from injecting a protein.
The randomized test of the idea: ACE-083. Acceleron built a follistatin-based molecule designed to act only in the muscle it was injected into. It is the closest thing to a controlled trial of local follistatin activity in people.
In healthy volunteers, it increased muscle volume by up to about 14.5% in the quadriceps muscle injected, but, in the authors' words, "no significant changes in mean muscle strength were observed."
In a randomized phase 2 trial in facioscapulohumeral muscular dystrophy (2022), total muscle volume rose 16.4% in the biceps versus placebo and 9.5% in the shin muscle, with less fat in the muscle. Yet "there were no consistent improvements in functional or patient-reported outcome measures in either group."
In a randomized phase 2 trial in Charcot-Marie-Tooth disease (2022), muscle volume rose 13.5% versus placebo and ankle strength improved, but patients "did not demonstrate greater functional improvement compared with those receiving placebo."
All three programs were terminated. The registry entries state plainly that development stopped because "functional secondary endpoints were not achieved."
That is the single most useful fact in this guide. A pharmaceutical-grade follistatin-based molecule, given under medical supervision, grew muscle on imaging and still did not make people function better.
Injected follistatin 344 in healthy people: nothing published. We searched PubMed and ClinicalTrials.gov on November 16, 2026 for human studies of follistatin administration for muscle growth. Every registry hit outside the gene-therapy trials used follistatin as a blood marker in exercise or metabolism research, not as a treatment. One industry-sponsored plasmid gene-therapy study (NCT06411366, 43 participants, completed 2023) is registered, but we found no peer-reviewed publication of its results.
What Testing of Black-Market Vials Found
In 2019, anti-doping chemists in Germany and Austria bought and analyzed 17 black-market products sold as follistatin. Their published findings, in Drug Testing and Analysis:
Only nine of the 17 actually contained follistatin. Some of the rest contained entirely different growth-promoting compounds, including mechano growth factor and a growth-hormone-releasing peptide.
All nine that did contain it carried a histidine tag, a laboratory purification handle that is not present on human follistatin, plus a high proportion of clumped (oligomerized) protein.
The histidine tag is useful to anti-doping labs, because it lets them tell an injected product apart from the body's own follistatin. For a buyer, it means something less comfortable: these were research-grade proteins expressed in bacteria, carrying a tag no medicine for humans would have, in a form that had partly aggregated.
PeptIQ.io / Follistatin 344 / 03
What was actually in the vials.
Anti-doping chemists bought 17 black-market products sold as follistatin and analyzed every one of them.
9 of 17
products sold as follistatin actually contained it.
8 of 17
contained no follistatin at all; some held other growth-promoting compounds instead.
9 of 9
of the genuine ones carried a histidine tag, a laboratory purification handle absent from human follistatin.
Oligomers
a high proportion of the protein had clumped together rather than staying in its working form.
Status in 2026
No FDA-approved follistatin product. Not in Appendix A of the Oct 30, 2026 HHS peptide policy. Prohibited in sport at all times under WADA S4.3.
Evidence, not marketing.Nov 2026
Source: Reichel, Gmeiner and Thevis, Drug Testing and Analysis 2019 (PubMed 31758732). The histidine tag is what lets anti-doping laboratories tell an injected product apart from the body's own follistatin.
Reported Harms
The only published human safety data on injected follistatin 344 is a case series, and it is not reassuring.
Ophthalmologists in Turkey described eleven male bodybuilders, average age about 37, who developed central serous chorioretinopathy after injecting follistatin-344. In that condition, fluid collects under the retina and blurs or distorts central vision. Eight had injected once and recovered over about two months. All three who had injected more than once developed recurrent disease. The authors concluded that follistatin-344 injection "can be considered as a risk factor" for the condition.
Beyond that, consider what is simply unknown. Myostatin and activin signaling is not muscle-specific; the same pathway operates in the ovary, the pituitary, bone, liver and tumors. Follistatin is studied in oncology because of its role in solid tumors. Systemic, long-term blockade of that pathway in healthy adults has never been studied.
Is Follistatin 344 a Peptide? Its 2026 Status
It is not a peptide, and that distinction has legal weight. The relevant text, from 21 CFR 600.3(h)(6):
> "A protein is any alpha amino acid polymer with a specific, defined sequence that is greater than 40 amino acids in size."
At 344 amino acids as a precursor and 315 as the circulating form, follistatin is far above that line. That makes it a protein and a biological product, which in the United States requires a Biologics License Application, not a new drug application, and which places it outside the peptide compounding pathways entirely. This is the same reasoning that keeps IGF-1 LR3 out of the peptide category.
The practical consequences in 2026:
No FDA-approved follistatin product exists for any use, in any form.
It is not in Appendix A of the HHS enforcement discretion policy published October 30, 2026, which covers six peptides. See our explainer on that policy.
"Research use only" labeling does not create a safe harbor. In a December 2025 warning letter to a compound seller, FDA cited the firm's own marketing claims, including one promoting follistatin expression, as evidence that products labeled research-grade were intended for human use, making them unapproved new drugs.
It is banned in sport at all times. The WADA Prohibited List places "myostatin-binding proteins (e.g. follistatin, myostatin propeptide)" under S4.3, agents preventing activin receptor IIB activation, prohibited both in and out of competition, as a non-specified substance. The same wording appears in the 2026 and 2027 lists. Anti-doping labs can detect the histidine-tagged product.
A 2026 Sports Medicine review of peptides marketed to patients grouped FS-344 with other unapproved compounds and made the general point directly: many of them show good results in animals, "but rigorous human safety data are scarce, and there is potential for serious harm."
Questions to Raise With a Licensed Clinician
If you are considering anything sold as follistatin, or you have already used it, these are worth asking:
What is my actual goal, and is there an approach with human outcome data behind it?
The follistatin-based drug that was tested properly grew muscle without improving function. Why would an untested product do better?
What would we monitor, and would we catch a problem before it became permanent?
I have new blurred or distorted vision. Could this be related, and should I see an ophthalmologist now?
If I compete in a tested sport, does this end my eligibility?
If you want a supervised route for anything in this space, use a licensed prescriber. Telehealth brands such as meds.you exist in this market; a clinician who can order labs and examine you is the point, not the brand.
How PeptIQ.io Helps
PeptIQ.io's Peptide Claim Auditor takes a link to an Instagram, TikTok, X or Reddit post and checks the claims in it against published research. It is built for exactly the kind of post that shows a before-and-after photo next to the word "follistatin" without citing a study. Our guide to vetting a peptide source and our certificate of analysis guide explain what a lab report can and cannot prove about a vial. If you and your clinician agree on a plan, the PeptIQ app keeps medications, labs and symptoms on one timeline you can share, and PeptIQ AI answers questions against your own log instead of a forum thread.
Talk to a Licensed Clinician
Talk to a licensed clinician before using anything sold as follistatin 344. This is an unapproved biological product with no human efficacy data, documented contamination and substitution in the supply chain, a published pattern of eye injury, and a permanent ban in tested sport. If you are already using it and have vision changes, seek care promptly and bring the product and its label with you.
Frequently Asked Questions
Q: What is follistatin 344?
A: Follistatin 344 is the longest form of follistatin, a natural protein that binds and neutralizes myostatin and activin. Myostatin limits muscle growth, so blocking it increases muscle mass in animals. The 344 refers to the number of amino acids in the precursor; the circulating form is 315 amino acids long.
Q: Does follistatin 344 build muscle in humans?
A: No human trial has tested injected follistatin 344 for muscle growth. The human data that exists comes from one-time gene therapy in muscle disease, and from a follistatin-based drug, ACE-083, that increased muscle volume on imaging in randomized trials but did not improve function and was discontinued.
Q: Is follistatin 344 a peptide?
A: No. Under 21 CFR 600.3(h)(6), anything longer than 40 amino acids is a protein. Follistatin is 315 to 344 amino acids, so it is a protein and a biological product, which is a different regulatory category from the peptides covered by compounding policies.
Q: Is follistatin 344 FDA approved?
A: No. There is no FDA-approved follistatin product for any use, and follistatin is not among the six peptides in Appendix A of the October 30, 2026 HHS compounding policy. Products sold as "research use only" are not approved medicines.
Q: What are the risks of follistatin 344?
A: The published human harm data is a case series of eleven bodybuilders who developed central serous chorioretinopathy, a fluid buildup under the retina, after injecting it; all three who injected more than once had recurrences. Longer-term effects of blocking this pathway throughout the body have never been studied in healthy people.
Q: Is follistatin banned in sport?
A: Yes. The WADA Prohibited List names follistatin under section S4.3 as a myostatin-binding protein, prohibited at all times, in and out of competition. Anti-doping laboratories have published methods that detect the histidine-tagged product sold on the black market.
Esch FS, Shimasaki S, Mercado M, et al. Structural characterization of follistatin: a novel follicle-stimulating hormone release-inhibiting polypeptide from the gonad. Mol Endocrinol. 1987;1(11):849-855. PubMed 3153465
Sidis Y, Mukherjee A, Keutmann H, et al. Biological activity of follistatin isoforms and follistatin-like-3. Endocrinology. 2006;147(7):3586-3597. PubMed 16627583
McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997;387(6628):83-90. PubMed 9139826
Lee SJ, McPherron AC. Regulation of myostatin activity and muscle growth. PNAS. 2001;98(16):9306-9311. PubMed 11459935
Rodino-Klapac LR, Haidet AM, Kota J, et al. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve. 2009;39(3):283-296. PubMed 19208403
Kota J, Handy CR, Haidet AM, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med. 2009;1(6):6ra15. PubMed 20368179
Chang F, Fang R, Wang M, et al. The transgenic expression of human follistatin-344 increases skeletal muscle mass in pigs. Transgenic Res. 2017;26(1):25-36. PubMed 27787698
Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy. Mol Ther. 2015;23(1):192-201. PubMed 25322757
Mendell JR, Sahenk Z, Al-Zaidy S, et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Mol Ther. 2017;25(4):870-879. PubMed 28279643
Glasser CE, Gartner MR, Wilson D, et al. Locally acting ACE-083 increases muscle volume in healthy volunteers. Muscle Nerve. 2018;57(6):921-926. PubMed 29486514
Statland JM, Campbell C, Desai U, et al. Randomized phase 2 study of ACE-083 in facioscapulohumeral muscular dystrophy. Muscle Nerve. 2022;66(1):50-62. PubMed 35428982
Thomas FP, Brannagan TH 3rd, Butterfield RJ, et al. Randomized phase 2 study of ACE-083 in patients with Charcot-Marie-Tooth disease. Neurology. 2022;98(23):e2356-e2367. PubMed 35545446
Reichel C, Gmeiner G, Thevis M. Detection of black market follistatin 344. Drug Test Anal. 2019;11(11-12):1675-1697. PubMed 31758732
Dağ U, Çağlayan M, Öncül H, Alakuş MF. Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series. Int Ophthalmol. 2020;40(11):3155-3161. PubMed 32671599
Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Med. 2026;56(8):1921-1935. PubMed 41966639
This article is educational content from PeptIQ.io. It is not medical advice. Talk with a licensed clinician before starting, stopping, or changing any peptide, medication, or injection practice.
For clinics: running peptide or GLP-1 programs for patients? See PeptIQ.io for providers: protocol templates, a patient app, and adherence tracking in one console.